基于基质辅助激光解析电离-傅里叶离子回旋共振质谱探究盐酸埃克替尼治疗的晚期非小细胞肺癌患者IgG1 Fc段半乳糖基化的性别特异性变化
Personalized biomarkers to monitor disease Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor, icotinib hydrochloride, using MALDI-FTICR MS
IgG主要依赖于其Fc段与其他蛋白质发生相互作用发挥功能。本研究共有31例IIIB或IV 非小细胞肺癌患者入组，采用基质辅助激光解析电离-傅里叶离子回旋共振质谱测定上述盐酸埃克替尼治疗的随访患者血清中IgG1 Fc段N-糖基化的相对含量。结果表明非小细胞肺癌患者血清中IgG1 Fc 段半乳糖基化及去半乳糖基化的相对含量随治疗时间发生显著变化，并且与性别有密切联系。IgG1 Fc 段半乳糖基化及去半乳糖基化的相对含量的性别特异性变化可能有助于理解表皮生长因子受体类药物的作用机制。
he functions of IgG mainly rely on the interactions of its Fc region with other proteins. 31 patients with stage IIIB and IV non-small cell lung cancer (NSCLC) were enrolled in this study. The levels of IgG1 Fc N-glycosylation in a series of serum samples from 31 NSCLC patients treated with icotinib hydrochloride were determined by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS). Our findings suggest that IgG1 Fc-galactosylation and Fc-agalactosylation levels of NSCLC patients changed with treatment time and gender was associated with changes in the IgG1 Fc- galactosylation and Fc-agalactosylation levels. Gender-specific changes in IgG1 Fc-galactosylation and Fc-agalactosylation may helpful in understanding the mechanism of EGFR drug action.
陈国强、刘辉、郭玉梅、王彦英、张力、李智立
肿瘤学基础医学生物科学研究方法、生物科学研究技术
盐酸埃克替尼非小细胞肺癌IgG1 Fc段半乳糖基化及去半乳糖基化性别
Non-small cell lung cancerIgG1 Fc-galactosylation and Fc-agalactosylationgendericotinib hydrochloride
陈国强,刘辉,郭玉梅,王彦英,张力,李智立.基于基质辅助激光解析电离-傅里叶离子回旋共振质谱探究盐酸埃克替尼治疗的晚期非小细胞肺癌患者IgG1 Fc段半乳糖基化的性别特异性变化[EB/OL].(2016-05-16)[2025-08-18].http://www.paper.edu.cn/releasepaper/content/201605-394.点此复制
评论